Infectious disease
Last week, HHS Secretary Alex Azar assumed all final authority in deciding new rules regarding food, medical devices and new medications.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
Roche launched its Elecsys Anti-SARS-CoV-2 S antibody test for markets that accept the CE Mark.
85% of participants in the trial of Actemra were from minority racial and ethnic groups, which are historically underrepresented in clinical studies.
He also said they would be able to deliver 100 million doses to the U.S. government in the “first few months of 2021.”
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
Cidara Therapeutics is hoping that its novel approach to influenza will prevent future “twindemic” double threats like the one we may face this year.
Robert Redfield, director of the U.S. Centers for Disease Control and Prevention, testified yesterday before the U.S. Senate Appropriations subcommittee on labor, health and human services, education and related agencies.
The manufacturing site will expand BioNTech’s COVID-19 vaccine production capacity by up to 750 million doses per year, or over 60 million doses per month, once fully operational, the company said.
PRESS RELEASES